TLR7/8 ligands R848 and imiquimod induce differentiation of bone marrow cells from patients with myelodysplastic syndrome towards mature neutrophils.

ABSTRACT: Myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML) arise as a consequence of acquisition and progressive accumulation of genetic and epigenetic modifications by haematopoietic stem and progenitor cells (HSPC) which result in an impaired cell differentiation and the clonal expansion of myeloid progenitors leading to blast-cell accumulation in bone marrow (BM) and myelodysplasia. TLRs are expressed on HSPC and play a role in modulating haematopoiesis by instructing commitment to the myeloid lineage, and therefore may have potential therapeutic application. We have determined the in vitro effect of R848 (TLR7/TLR8 agonist) and Imiquimod (TLR7 agonist), on differentiation, apoptosis and cell viability in primary cultures of bone marrow samples from MDS (n = 6) and AML patients (

SUBMITTER: Villamon E 

PROVIDER: S-EPMC12381240 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature